Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
November 17, 2021
RegMed Investors’ (RMi) closing bell: sentiment’s headwinds obliterate sector’s share pricing
November 16, 2021
RegMed Investors’ (RMi) closing bell: wham-bam and a no thank you
November 15, 2021
RegMed Investors’ (RMi) closing bell: sector declines - it’s not transitory, infamous current terms
November 12, 2021
RegMed Investors’ (RMi) closing bell: gravity is more than a force, it’s a sector disorder
November 11, 2021
RegMed Investors’ (RMi) closing bell: from an extreme downside to a barely downslide
November 10, 2021
RegMed Investors’ (RMi) closing bell: yet another pull-back that cut to the bone as the sector bleeds-out
November 9, 2021
RegMed Investors’ (RMi) closing bell: sector takes yet another dive
November 8, 2021
RegMed Investors’ (RMi) closing bell: the sector faded even as small-cap stocks led on the upside and held near their highs
November 6, 2021
RegMed Investors’ (RMi) closing bell: bag and tag ‘em, as LPS (loss-per-share) earnings define the week’s share pricing endings
November 4, 2021
RegMed Investors’ (RMi) closing bell: not quite wrong and almost totally correct
35 companies, 1 interpreter!
Insight, foresight and recommendation
Stemline Therapeutics (STML) -- STML opened on 1/2/18 at $15.65 and closed on 3/31 at $15.85 and March at $16.75 with a high (3/6/18) at 17.20 ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.